Patent application number | Description | Published |
20080269192 | Chiral Fused [1,2]Imidazo[4,5-C] Ring Compounds - Fused [1,2]imidazo[4,5-c] ring compounds (e.g., imidazo[4,5-c]quinolines, 6,7,8,9-tetrahydroimidazo[4,5-c]quinolines, imidazo[4,5-c]naphthyridines, and 6,7,8,9-tetrahydroimidazo[4,5-c]naphthyridines) with a —CH(—X | 10-30-2008 |
20090018122 | Aryloxy and Arylalkyleneoxy Substituted Imidazoquinolines - Imidazoquinoline compounds with an aryloxy or arylalkyleneoxy or hydroxy substituent at the 6, 7, 8, or 9-position, pharmaceutical compositions containing the compounds, intermediates, and methods of use of these compounds as immunomodulators, for modulating cytokine biosynthesis in animals and in the treatment of diseases including viral and neoplastic diseases, are disclosed. | 01-15-2009 |
20090023720 | 2-Amino 1H-Imidazo Ring Systems and Methods - 1H-Imidazo ring systems (e.g., imidazopyridines, imidazoquinolines, imidazonaphthyridines, 6,7,8,9-tetrahydro imidazoquinolines and imidazonaphthyridines) with an amino substituent at the 2-position, pharmaceutical compositions containing these compounds, methods of making the compounds, intermediates, and methods of use of these compounds as immunomodulators, for modulating cytokine biosynthesis in animals and in the treatment of diseases including viral and neoplastic diseases, are disclosed. | 01-22-2009 |
20090029988 | Hydroxyalkyl Substituted Imidazoquinolines - Certain imidazoquinolines with a hydroxymethyl or hydroxyethyl substituent at the 2-position, pharmaceutical compositions containing the compounds, intermediates, methods of making and methods of use of these compounds as immunomodulators, for preferentially inducing IFN-α biosynthesis in animals and in the treatment of diseases including viral and neoplastic diseases are disclosed. | 01-29-2009 |
20090030031 | Method of Preferentially Inducing the Biosynthesis of Interferon - A method of preferentially inducing IFN-α biosynthesis in an animal comprising administering certain imidazo[4,5-c] ring compounds with a hydroxymethyl or hydroxyethyl substituent at the 2-position or pharmaceutical compositions containing the compounds, intermediates, methods of making, and methods of using these compounds a immunomodulators for treatment of diseases including viral and neoplastic diseases comprising preferentially inducing IFN-α biosynthesis in an animal are disclosed. | 01-29-2009 |
20090030341 | SAMPLE RELEASE SYSTEM - Devices to process a sample are configured to releasably attach a sample acquisition device to a drive mechanism that provides rotational and/or vibrational motion to the sample acquisition device. The devices can be used in sample processing methods to dislodge sample materials from the sample acquisition device. Sample processing methods using rotational or vibrational motion may further include the use of a liquid medium into which the sample is released. Sample processing methods may further include the detection of an analyte in the sample. | 01-29-2009 |
20090030342 | APPARATUS AND METHOD FOR RELEASING A SAMPLE OF MATERIAL - A first aspect of the present invention provides for devices to facilitate the release of sample materials from sample acquisition devices. The device comprises an abrasion element comprising at least one constriction or projection. A second aspect of the present invention provides for methods in which to use the devices to facilitate the release of sample materials from a sample acquisition device. Optionally, the device may contain at least one reagent to facilitate the release and/or detection of a microorganism, or component thereof, in a sample. Preferably, the devices and methods may be used in conjunction with a liquid medium in which the sample may be further processed. | 01-29-2009 |
20090042925 | OXIME SUBSTITUTED IMIDAZOQUINOLINES - Imidazo ring compounds (e.g., imidazoquinolines, 6,7,8,9-tetrahydroimidazoquinolines, imidazonaphthyridines, and imidazopyridines) with an oxime substituent at the 2-position, pharmaceutical compositions containing the compounds, intermediates, and methods of use of these compounds as immunomodulators, for inducing cytokine biosynthesis in animals and in the treatment of diseases including viral and neoplastic diseases are disclosed. | 02-12-2009 |
20090062328 | Oxime and Hydroxylamine Substituted Imidazo[4,5-c] Ring Compounds and Methods - Imidazo[4,5-c] ring compounds, (e.g. imidazo[4,5-c]pyridines, imidazo[4,5-c]quinolines, 6,7,8,9-tetrahydro imidazo[4,5-c]quinolines, imidazo[4,5-c]naphthyridine, and 6,7,8,9-tetrahydro imidazo[4,5-c]naphthyridine compounds) having an oxime or hydroxylamine substituent at the 2-position, pharmaceutical compositions containing the compounds, intermediates, and methods of making and methods of use of these compounds as immunomodulators, for modulating cytokine biosynthesis in animals and in the treatment of diseases including viral and neoplastic diseases are disclosed. | 03-05-2009 |
20090069299 | Pyrazolo[3,4-c]Quinolines, Pyrazolo[3,4-c]Naphthyridines, Analogs Thereof, and Methods - Pyrazolo[3,4-c]quinolines, pyrazolo[4,5-c]naphthyridines, and analogs thereof, eg., 6,7,8,9-tetrahydro pyrazolo[3,4-c]quinolines, and, pharmaceutical compositions containing the compounds, intermediates, methods of making these compounds, and methods of use of these compounds as immunomodulators, for inhibiting cytokine biosynthesis in animals and in the therapeutic or prophylactic treatment of diseases by inhibiting cytokine biosynthesis are disclosed. | 03-12-2009 |
20090069314 | Hydroxyalkyl Substituted Imidazoquinoline Compounds and Methods - Certain imidazoquinolines with a hydroxymethyl or hydroxyethyl substituent at the 2-position, and an aryl or heteroaryl substituent at the 7-position, pharmaceutical compositions containing the compounds, intermediates, methods of making and methods of use of these compounds as immunomodulators, for preferentially inducing IFN-α biosynthesis in animals and in the treatment of diseases including viral and neoplastic diseases are disclosed. | 03-12-2009 |
20090075980 | Pyrazolopyridines and Analogs Thereof - Pyrazolopyridin-4-amines, pyrazoloquinolin-4-amines, pyrazolonaphthyridin-4-amines, 6,7,8,9-tetrahydropyrazoloquinolin-4-amines, and prodrugs thereof, pharmaceutical compositions containing the compounds, intermediates, methods of making, and methods of use of these compounds as immunomodulators, for inducing or inhibiting cytokine biosynthesis in animals and in the treatment of diseases including viral and neoplastic diseases, are disclosed. | 03-19-2009 |
20090099161 | Substituted Imidazoquinolines and Imidazonaphthyridines - Imidazoquinolines and imidazonaphthyridines with a substituent containing a functional group, e.g., an amide, sulfonamide, urea, or heterocyclyl group, at the 6, 7, 8, or 9-position, pharmaceutical compositions containing the compounds, intermediates, methods of making and methods of use of these compounds as immunomodulators, for inducing cytokine biosynthesis in animals and in the treatment of diseases including viral and neoplastic diseases are disclosed. | 04-16-2009 |
20090105295 | HYDROXYLAMINE SUBSTITUTED IMIDAZOQUINOLINES - Imidazo ring compounds (e.g., imidazoquinolines, 6,7,8,9-tetrahydroimidazoquinolines, imidazonaphthyridines, and imidazopyridines) with a hydroxylamine substituent at the 2-position, pharmaceutical compositions containing the compounds, intermediates, and methods of use of these compounds as immunomodulators, for inducing cytokine biosynthesis in animals and in the treatment of diseases including viral and neoplastic diseases are disclosed. | 04-23-2009 |
20090176821 | Amide and Carbamate Derivatives of Alkyl Substituted N-[4-(4-Amino-1H-Imidazo[4,5-C] Quinolin-1-YL)Butyl]Methanesulfonamides and Methods - Amide and carbamate derivatives of N-[4-(4-amino-1H-imidazo[4,5-c]quinolin-1-yl)butyl]methanesulfonamides with an ethyl, methyl, or n-propyl substituent at the 2-position, pharmaceutical compositions containing these compounds, methods of making the compounds, and methods of use of these compounds in modulating the immune system, for inducing cytokine biosyn-thesis in animals and in the treatment of diseases including viral and neoplastic diseases, are disclosed. | 07-09-2009 |
20090253695 | Hydroxyalkyl Substituted Imidazonaphthyridines - Certain imidazonaphthyridines with a hydroxymethyl or hydroxyethyl substituent at the 2-position, pharmaceutical compositions containing the compounds, intermediates, methods of making and methods of use of these compounds as immunomodulators, for preferentially inducing IFN-α biosynthesis in animals and in the treatment of diseases including viral and neoplastic diseases are disclosed. | 10-08-2009 |
20090318435 | PYRAZOLOPYRIDINES AND ANALOGS THEREOF - Pyrazolopyridin-4-amines, pyrazoloquinolin-4-amines, pyrazolonaphthyridin-4-amines, and 6,7,8,9-tetrahydropyrazoloquinolin-4-amines, pharmaceutical compositions containing the compounds, intermediates, methods of making, and methods of use of these compounds as immunomodulators, for inducing or inhibiting cytokine biosynthesis in animals and in the treatment of diseases including viral and neoplastic diseases, are disclosed. | 12-24-2009 |
20100069427 | Oxime and Hydroxylamine Substituted Imidazo[4,5-c] Ring Compounds and Methods - Imidazo[4,5-c] ring compounds, (e.g. imidazo[4,5-c]pyridines, imidazo[4,5-c]quinolines, 6,7,8,9-tetrahydro imidazo[4,5-c]quinolines, imidazo[4,5-c]naphthyridine, and 6,7,8,9-tetrahydro imidazo[4,5-c]naphthyridine compounds) having an oxime or hydroxylamine substituent at the 2-position, pharmaceutical compositions containing the compounds, intermediates, and methods of making and methods of use of these compounds as immunomodulators, for modulating cytokine biosynthesis in animals and in the treatment of diseases including viral and neoplastic diseases are disclosed. | 03-18-2010 |
20100158928 | IMMUNE RESPONSE MODIFIER COMPOSITIONS AND METHODS - The present invention provides an immune response modifier (IRM) composition that includes an IRM moiety and a second active moiety covalently linked to the IRM moiety, wherein the covalent link comprises a labile bond directly attached to the IRM moiety. | 06-24-2010 |
20100190171 | MICROORGANISM CONCENTRATION PROCESS - A process for capturing or concentrating microorganisms for detection or assay comprises (a) providing a concentration agent that comprises an amorphous metal silicate and that has a surface composition having a metal atom to silicon atom ratio of less than or equal to about 0.5, as determined by X-ray photoelectron spectroscopy (XPS); (b) providing a sample comprising at least one microorganism strain; and (c) contacting the concentration agent with the sample such that at least a portion of the at least one microorganism strain is bound to or captured by the concentration agent. | 07-29-2010 |
20100209961 | MICROORGANISM CONCENTRATION PROCESS AND AGENT - A process for capturing or concentrating microorganisms for detection or assay comprises (a) providing a concentration agent that comprises diatomaceous earth bearing, on at least a portion of its surface, a surface treatment comprising a surface modifier comprising titanium dioxide, fine-nanoscale gold or platinum, or a combination thereof; (b) providing a sample comprising at least one microorganism strain; and (c) contacting the concentration agent with the sample such that at least a portion of the at least one microorganism strain is bound to or captured by the concentration agent. | 08-19-2010 |
20100247592 | PROCESS FOR LIMITING THE GROWTH OF MICROORGANISMS - A process for limiting the growth of microorganisms comprises (a) providing an antimicrobial agent comprising fine-nanoscale gold on a support medium comprising nanoparticulate titania, the fine-nanoscale gold having been deposited on the support medium by physical vapor deposition; and (b) contacting at least one microorganism with the antimicrobial agent. | 09-30-2010 |
20100248214 | MICROORGANISM CONCENTRATION PROCESS - A process for capturing or concentrating microorganisms for detection or assay comprises (a) providing a particulate concentration agent that comprises gamma-FeO(OH); (b) providing a fluid sample comprising at least one microorganism strain; and (c) contacting the concentration agent with the sample such that at least a portion of the concentration agent is dispersed in the sample and at least a portion of the at least one microorganism strain is bound to or captured by the concentration agent. | 09-30-2010 |
20100317684 | Amide and Carbamate Derivatives of N-{2-[4-Amino-2- (Ethoxymethyl)-1H-Imidazo[4,5-c]Quinolin-1-Yl]-1,1-Dimethylethyl} Methanesulfonamide and Methods - Amide and carbamate derivatives N-{2-[4-amino-2-(ethoxymethyl)-1H-imidazo[4,5-c]quinolin- | 12-16-2010 |
20110146419 | SAMPLE ACQUISITION DEVICE - A sample acquisition device includes a capillary array configured to draw in a sample and retain the sample by capillary action. The capillary array may be coupled to an elongated member, such as a stem or a hollow tube, which defines a longitudinal axis extending in a first direction. In some embodiments, the capillary array defines a major sample acquisition surface that extends in a second direction different than the first direction. A ratio of the major sample acquisition surface area to maximum volume retained by the capillary array may be selected to minimize physical binding between the capillary array and sample. In some embodiments, the device may include a feedback mechanism to indicate the relative pressure applied to a sample source with the sample acquisition device. In addition, in some embodiments, the sample acquisition device may include a suction source to help draw the sample into the capillary array. | 06-23-2011 |
20110179887 | SAMPLE ACQUISITION DEVICE - A sample acquisition device includes a body comprising a plurality of sample acquisition regions defined by at least a first wall and a second wall oriented nonparallel to the first wall. In some embodiments, the body defines a plurality of apertures that define a plurality of sample acquisition regions. In other embodiments, the walls extend from the body, and the sample acquisition regions are defined between the walls. The sample acquisition regions may be configured in some embodiments such that a user may acquire a sample by rotating the body in a first direction relative to a sample source and may release the sample by rotating the body in a second direction that is substantially opposite to the first direction. When rotated in the first direction, at least one of the first or second walls defines a surface that is inclined into a sample acquisition region. | 07-28-2011 |
20110183398 | MICROORGANISM-CAPTURING COMPOSITIONS AND METHODS - The invention relates to compositions, methods, devices, and kits for non-specifically isolating bacterial cells. The compositions comprise a solid support which has a surface comprising a combination of a carbohydrate and a biotin-binding protein, wherein the protein is covalently bonded to the carbohydrate, and wherein the protein is linked to the solid support via the carbohydrate; and at least one of 1) a plurality of bacterial cells non-specifically bound to the combination of the carbohydrate and the protein or 2) an amphiphilic glycoside of a steroid or triterpene. The methods, devices, and kits include at least one of these compositions. | 07-28-2011 |
20110207725 | CHIRAL FUSED [1,2]IMIDAZO[4,5-c] RING COMPOUNDS - Fused [1,2]imidazo[4,5-c] ring compounds (e.g., imidazo[4,5-c]quinolines, 6,7,8,9-tetrahydroimidazo[4,5-c]quinolines, imidazo[4,5-c]naphthyridines, and 6,7,8,9-tetrahydroimidazo[4,5-c]naphthyridines) with a —CH(—X | 08-25-2011 |
20110293654 | SUBSTITUTED CHIRAL FUSED [1,2]IMIDAZO[4,5-c] RING COMPOUNDS - Substituted fused [1,2]imidazo[4,5-c] ring compounds (e.g., imidazo[4,5-c]quinolines, 6,7,8,9-tetrahydroimidazo[4,5-c]quinolines, imidazo[4,5-c]naphthyridines, and 6,7,8,9-tetrahydroimidazo[4,5-c]naphthyridines) with a —CH(—R | 12-01-2011 |
20120232057 | CHIRAL FUSED [1,2]IMIDAZO[4,5-c] RING COMPOUNDS - Fused [1,2]imidazo[4,5-c] ring compounds (e.g., imidazo[4,5-c]quinolines, 6,7,8,9-tetrahydroimidazo[4,5-c]quinolines, imidazo[4,5-c]naphthyridines, and 6,7,8,9-tetrahydroimidazo[4,5-c]naphthyridines) with a —CH(—X | 09-13-2012 |
20130273593 | STERILIZATION INDICATORS INCLUDING A NEUTRALIZER AND METHODS - Sterilization indicators that include a neutralizer, such indicators useful for testing the effectiveness of a sterilization procedure by measuring the activity of an active enzyme whose activity is correlated with the survival of microorganisms. | 10-17-2013 |
20130273594 | STERILIZATION INDICATORS INCLUDING A POROUS CARRIER AND METHODS - Sterilization indicators that include a unique porous carrier, such indicators useful for testing the effectiveness of a sterilization procedure by measuring the activity of an active enzyme whose activity is correlated with the survival of microorganisms. | 10-17-2013 |
20140011253 | MICROORGANISM CONCENTRATION AGENT AND METHOD OF MAKING - A concentration agent for capture of microorganisms, including diatomaceous earth bearing, on at least a portion of its surface, a surface treatment comprising a surface modifier comprising titanium dioxide, fine-nanoscale gold or platinum, or a combination thereof, and methods for making the concentration agent. | 01-09-2014 |
20150023990 | ALKOXY SUBSTITUTED IMIDAZOQUINOLINES - Imidazoquinoline compounds with an alkoxy substituent at the 6, 7, 8, or 9-position, pharmaceutical compositions containing the compounds, intermediates, methods of making, and methods of use of these compounds as immunomodulators, for inducing or inhibiting cytokine biosynthesis in animals and in the treatment of diseases including viral, and neoplastic, are disclosed. | 01-22-2015 |